Yes — telehealth providers can legally prescribe controlled substances in 2026 without an in-person visit. On December 31, 2025, the DEA and HHS jointly issued a fourth temporary extension of COVID-era telemedicine prescribing flexibilities, keeping them active through December 31, 2026. This means patients seeking ADHD medications, anti-anxiety prescriptions, certain sleep aids, and other controlled substances can continue to access care via video visit — no in-person evaluation required.

Can Telehealth Prescribe Controlled Substances in 2026?

Under normal circumstances, the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 requires at least one in-person medical evaluation before a practitioner can prescribe a controlled substance remotely. The COVID-19 public health emergency suspended that requirement in 2020, and the DEA has extended those flexibilities every year since.

The 2026 extension — published in the Federal Register on December 31, 2025 — is the fourth consecutive renewal. It is effective January 1 through December 31, 2026, and applies to all DEA-registered practitioners operating under state licensure. Patients are not required to take any new action; existing telehealth relationships continue without interruption.

Source: DEA Press Release, December 31, 2025 | HHS.gov announcement | Federal Register 2025-24123

Which Controlled Substances Can Be Prescribed via Telehealth?

The extension covers Schedule II through Schedule V controlled substances, which includes the most commonly prescribed medications for ADHD, anxiety, sleep disorders, and chronic pain management. The table below shows what is and isn’t available via telehealth in 2026.

Medication ClassDEA ScheduleCommon ExamplesTelehealth-Eligible 2026?
ADHD stimulantsIIAdderall, Vyvanse, Ritalin, Concerta✅ Yes — audio-video required
BenzodiazepinesIVXanax (alprazolam), Klonopin (clonazepam), Valium✅ Yes — audio-video required
Sleep aidsIVAmbien (zolpidem), Lunesta (eszopiclone)✅ Yes — audio-video required
Opioid analgesicsII–IIIHydrocodone, codeine combinations✅ Yes — audio-video required
Opioid use disorder RxIIISuboxone (buprenorphine/naloxone)✅ Yes — audio-only also permitted
GabapentinoidsV (state varies)Gabapentin✅ Yes in most states
Stimulant-like sleep aidsIVProvigil (modafinil)✅ Yes

Key caveat: Audio-only (phone-only) visits are generally not sufficient for Schedule II prescriptions. An audio-video platform that meets HIPAA standards is required for stimulants and opioids. Audio-only is permitted for Schedule III–V substances used in opioid use disorder treatment under specific circumstances outlined in the extension rule.

What Does the DEA Still Require from Telehealth Providers?

The extension maintains the COVID-era flexibilities but does not eliminate all oversight. Providers prescribing controlled substances via telehealth in 2026 must:

  • Hold an active DEA registration and a valid state medical license
  • Use a HIPAA-compliant audio-video platform for Schedule II substances
  • Conduct a clinically appropriate evaluation — history, symptom review, and appropriate documentation
  • Check the patient’s state Prescription Drug Monitoring Program (PDMP) database before prescribing Schedule II–IV drugs
  • Follow all state-specific prescribing laws, which may be stricter than the federal floor
  • Maintain records in accordance with DEA and state requirements

Providers are also expected to exercise clinical judgment about whether a patient is an appropriate candidate for a controlled substance via telehealth alone — prescribing is not automatic based on patient request.

What Happens After December 31, 2026?

This is the most frequently asked question — and the most important one for patients on ongoing controlled-substance therapy.

The DEA has been working toward a permanent Special Registration for Telemedicine framework since 2023. As of mid-2026, the permanent rule has not been finalized. The fourth extension explicitly exists to provide additional runway for rulemaking. Here is what the proposed permanent rule would likely require (based on the most recent NPRM drafts):

  • Mandatory PDMP checks for every controlled-substance prescription
  • Verification of patient identity at the first telehealth visit
  • DEA data reporting requirements for telemedicine prescribers
  • A tiered credentialing framework for providers
  • Potential restrictions on which Schedule II drugs can be initiated without at least one in-person visit under certain circumstances

What this means for patients: If you are currently receiving ADHD, anxiety, or pain medication through telehealth, you should not face disruption before January 1, 2027. What happens after that date depends on whether the DEA finalizes its permanent rule before the extension lapses. Every previous extension came shortly before the prior one expired — the pattern suggests continued access is likely, but no guarantee exists. Your provider should keep you informed.

How Does the DEA Extension Affect ADHD Patients Specifically?

ADHD is among the conditions most affected by this policy debate. Adderall and Vyvanse are Schedule II controlled substances, meaning they carry the highest level of oversight in the non-narcotic category. Before the COVID flexibilities, obtaining a new ADHD prescription via telehealth — without any prior in-person visit — was not permitted under the Ryan Haight Act.

The extension preserves access for:

  • New patients starting an ADHD evaluation and prescription entirely online
  • Existing patients who moved states and need to transfer care without an in-person visit
  • Patients between providers who need a bridge prescription while establishing with a new clinician

One practical note: even under the extension, a legitimate telehealth ADHD evaluation still requires a thorough clinical assessment. Providers who are simply rubber-stamping prescriptions without evaluation risk DEA sanctions and potential loss of prescribing authority. Omnia’s clinicians conduct comprehensive ADHD screenings that align with current APA guidelines.

Anxiety and Sleep Medications: What Changes?

Benzodiazepines (Schedule IV) and common sleep aids like zolpidem are also in scope. The 2026 extension allows video-visit prescribing for:

  • Generalized anxiety disorder (GAD) managed with benzodiazepines
  • Panic disorder treated with clonazepam or alprazolam
  • Insomnia requiring zolpidem, eszopiclone, or related agents

Providers are expected to document the rationale for a controlled-substance choice over non-controlled alternatives (e.g., SSRIs for anxiety, cognitive behavioral therapy for insomnia). This is standard-of-care documentation, not a barrier specific to telehealth — it applies to in-person visits as well.

Chronic Pain and Opioid Prescribing via Telehealth

Opioid prescribing via telehealth carries additional complexity. The extension technically permits Schedule II opioid prescribing via audio-video, but most responsible telehealth platforms — including Omnia — apply conservative clinical criteria for initiating opioids remotely:

  • Patients with established, documented chronic pain conditions
  • Continuity of care (transferring from a prior in-person prescriber)
  • PDMP review showing no concurrent prescribing concerns
  • Regular follow-up visits every 30–90 days, depending on drug and dose

Initiating new opioid therapy for acute pain via telehealth alone is generally not appropriate and is outside most reputable providers’ clinical scope.

How to Get a Controlled-Substance Prescription via Telehealth in 2026

If you currently take or are seeking a prescription for a controlled substance and prefer not to visit an office, here is what the process looks like at Omnia:

  1. Request an appointment through our medication refill and controlled-substance service
  2. Complete intake paperwork including medical history, current medications, and symptom questionnaires
  3. Attend a video visit with a licensed clinician in your state
  4. PDMP check is run by our provider before any controlled-substance Rx is issued
  5. Pharmacy sends prescription electronically — Schedule II drugs require e-prescribing per DEA rules
  6. Follow-up is scheduled — most controlled substances require at least quarterly check-ins

The entire process can be completed without leaving home for the duration of 2026. If the permanent rule changes things in 2027, we will notify all affected patients well in advance.

Frequently Asked Questions

Can telehealth prescribe Adderall without an in-person visit in 2026? Yes. Under the DEA’s fourth extension, licensed clinicians can prescribe Schedule II stimulants like Adderall or Vyvanse via audio-video telehealth without a prior in-person evaluation through December 31, 2026. A thorough clinical assessment is still required during the video visit.

Will I need to see a doctor in person to keep my ADHD or anxiety prescription in 2027? Not necessarily. The DEA is finalizing a permanent telemedicine rule, but has not released it as of September 2026. Past behavior suggests another extension or a permanent framework will be in place before the current one expires. Your telehealth provider should update you when details are confirmed.

Does the extension apply to buprenorphine (Suboxone) for opioid use disorder? Yes — and with greater flexibility. Schedule III substances used in opioid use disorder treatment can be prescribed via audio-only (phone) visits, unlike Schedule II drugs that require audio-video.

Can a telehealth provider prescribe benzos like Xanax or Klonopin online? Yes. Benzodiazepines are Schedule IV controlled substances, and the 2026 extension covers them. However, providers are expected to evaluate whether a controlled substance is clinically appropriate, document the rationale, and schedule follow-up visits.

Is it safe to start a controlled substance for the first time via telehealth? For many conditions — ADHD, anxiety, insomnia — beginning treatment via telehealth is clinically appropriate when accompanied by a thorough evaluation. For complex pain conditions or opioid therapy, most responsible providers prefer at least one in-person baseline evaluation. Speak with your clinician about what makes sense for your situation.

Ready to review or start your prescription? Our licensed providers are available for same-day and next-day video visits. Visit our medication refill service to schedule a controlled-substance evaluation or refill appointment — no waiting room, no commute.

This post is for informational purposes only and does not constitute medical or legal advice. Controlled-substance prescribing decisions are made by licensed clinicians on a case-by-case basis.